New evidence on revolutionary brain pacemaker for Parkinson's Disease patients

March 25, 2002

Less than 7% of all Parkinson Disease (PD) patients across Europe that could benefit from deep brain stimulation have benefited from the Activa® Parkinson's Control Therapy, despite it being the most significant advance in the treatment of Parkinson's in more than 30 years.

The European Parkinson's Disease Association (EPDA) announced today new evidence on the current uptake of deep brain stimulation for Parkinson's disease patients and despite its success there are still large numbers of patients waiting or denied access to the therapy.

Deep brain stimulation uses Medtronic's Activa® Parkinson's Control Therapy which is a pioneering treatment for patients with Parkinson's disease. It was launched by Medtronic with the support of the EPDA to great acclaim in Europe four years ago in 1998, however considerably low numbers of patients with Parkinson's disease have received the treatment since that period.

The World Health Organisation (WHO) has estimated that there are four million people with Parkinson's disease worldwide1. Currently Parkinson's disease is ranked as the fourth most frequent disorder of the nervous system, after epilepsy, cerebrovascular disease and Alzheimer's2. It has been estimated that across Europe, approximately 20% of all PD patients could benefit from deep brain stimulation3.

However, it was revealed today that approximately 7%* of patients suitable for surgical treatment across Europe have received deep brain stimulation in the key G5 European countries (France, Italy, Germany, Spain and UK) since it was launched four years ago. Switzerland is leading the way with the UK bottom of the G5 countries in terms of accessibility to deep brain stimulation for appropriate patients. The estimated percentage of new suitable PD patients per year receiving deep brain stimulation therapy in Europe is as follows: 29.4% of patients in Switzerland, 9.8% in France, 9.3% in the Netherlands, 8.4% in Spain, 5.3% in Italy, 5.2% in Germany with only 4.6% of patients in the UK. This equates to approximately 7% uptake in patients suitable for surgical treatment within the G5 countries3.

"Deep brain stimulation using Medtronic's Activa® Parkinson's Control Therapy is a major advancement in the treatment of Parkinson's disease as it is an effective approach to treating the disabling symptoms of the disease," said Professor Alim Benabid, the pioneer of this revolutionary treatment and Chairman of Neurosurgery at the University Joseph Fourier in Grenoble, France.

"Increasing numbers of patients are receiving this therapy in Europe but in some countries the rate of uptake is not what one might expect. Clinicians in Europe have over 15 years of experience with deep brain stimulation and the therapy can no longer be considered experimental in any way as it has a proven safety and efficacy profile over this period. EU approval in 1998 and FDA approval in the USA in January 2002 were milestones in the development of this therapy that can transform patients' lives for the better."

This evidence has also helped to identify a number of barriers that exist for medical professionals with respect to deep brain stimulation treatment. The main ones being inconsistent funding support within and between each country, lack of interaction between all specialists involved in the procedure and low awareness of the treatment among general practitioners (GP)/referring physicians.

Mary Baker, President of the EPDA, commented, "The EPDA strongly believes that it is essential that patients with Parkinson's disease receive the best treatment appropriate for their needs. The most important concern for patients with Parkinson's disease is improving their quality of life. More attention needs to be given to treatments that help to advance this, such as deep brain stimulation using the Activa® Parkinson's Control Therapy. The EPDA would like to see access to therapies such as deep brain stimulation improve for appropriate patients across Europe."

Professor of Neurosurgery at Imperial College London, Tipu Aziz, stressed how important dialogue between consultant and patient is, "Doctors need to discuss with their patients all appropriate treatment options for Parkinson's disease. In addition patients need to initiate conversation on therapy with their general practitioner/family physician. Referrals should then be made to a specialist neurologist or neurosurgeon where appropriate for deep brain stimulation."

The cause of Parkinson's is unknown, but the symptoms stem from the degeneration of neurons (brain cells) that produce dopamine. Dopamine is a neurotransmitter that enables communication among the brain cells involved in motor control. Activa® Therapy's electrical stimulation acts on these malfunctioning circuits in the brain using an implanted medical device akin to a cardiac pacemaker.

"Before the onset of Parkinson's I had it all; a good quality of life, an interesting and responsible job and, most importantly, my health," Mike Robins commented, a patient who has had Parkinson's disease for 6 years and was treated with the Activa® Therapy in 1999. "As a result of deep brain stimulation my life, once again, changed immeasurably. I no longer have this debilitating tremor that made me an object of sympathy for some, and horror for others. I am once again the confident person I was before Parkinson's started. I've been given back my life."
-end-
References:
1 WHO Parkinson's disease fact sheet. April 1997.
2 Association of the British Pharmaceutical Industry publication, Target Parkinson's, April 1998.
3 Data on file. Medtronic Europe (* Calculated for annual incidence figures per country).


Notes for Editors

In some countries across Europe, deep brain stimulation is being offered to patients with movement disorders other than Parkinson's disease, such as essential tremor and dystonia.

If you have any questions and/or would like to speak to Mary Baker, President of the EPDA, an expert in this area, a patient affected by this disease, or would like b-roll footage/photography, please contact:

Amanda Boswell or Roseann Ward
Ketchum, London
Tel: +44 (0) 207 611 3500
Email: amanda.boswell@ketchum.com

Lizzie Graham
EPDA Liaison/Project Manager
4 Golding Road
Sevenoaks
Kent TN13 3NJ, United Kingdom
Tel/Fax: +44 (0) 1732 457 683
Email: Lizzie@epda.demon.co.uk
http://www.epda.eu.com
http://www.epdaconferences.org

Registered Office:
Rue Montoyer 47, B-1000
Bruxelles, Belgium

Ketchum UK

Related Brain Articles from Brightsurf:

Glioblastoma nanomedicine crosses into brain in mice, eradicates recurring brain cancer
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research from the University of Michigan shows.

Children with asymptomatic brain bleeds as newborns show normal brain development at age 2
A study by UNC researchers finds that neurodevelopmental scores and gray matter volumes at age two years did not differ between children who had MRI-confirmed asymptomatic subdural hemorrhages when they were neonates, compared to children with no history of subdural hemorrhage.

New model of human brain 'conversations' could inform research on brain disease, cognition
A team of Indiana University neuroscientists has built a new model of human brain networks that sheds light on how the brain functions.

Human brain size gene triggers bigger brain in monkeys
Dresden and Japanese researchers show that a human-specific gene causes a larger neocortex in the common marmoset, a non-human primate.

Unique insight into development of the human brain: Model of the early embryonic brain
Stem cell researchers from the University of Copenhagen have designed a model of an early embryonic brain.

An optical brain-to-brain interface supports information exchange for locomotion control
Chinese researchers established an optical BtBI that supports rapid information transmission for precise locomotion control, thus providing a proof-of-principle demonstration of fast BtBI for real-time behavioral control.

Transplanting human nerve cells into a mouse brain reveals how they wire into brain circuits
A team of researchers led by Pierre Vanderhaeghen and Vincent Bonin (VIB-KU Leuven, Université libre de Bruxelles and NERF) showed how human nerve cells can develop at their own pace, and form highly precise connections with the surrounding mouse brain cells.

Brain scans reveal how the human brain compensates when one hemisphere is removed
Researchers studying six adults who had one of their brain hemispheres removed during childhood to reduce epileptic seizures found that the remaining half of the brain formed unusually strong connections between different functional brain networks, which potentially help the body to function as if the brain were intact.

Alcohol byproduct contributes to brain chemistry changes in specific brain regions
Study of mouse models provides clear implications for new targets to treat alcohol use disorder and fetal alcohol syndrome.

Scientists predict the areas of the brain to stimulate transitions between different brain states
Using a computer model of the brain, Gustavo Deco, director of the Center for Brain and Cognition, and Josephine Cruzat, a member of his team, together with a group of international collaborators, have developed an innovative method published in Proceedings of the National Academy of Sciences on Sept.

Read More: Brain News and Brain Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.